INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Systematic review / meta-analysis / 2024

Once-weekly semaglutide 2.4 mg produced significant, sustained weight loss and improved cardiometabolic markers in non-diabetic overweight or obese adults.

A systematic review and meta-analysis of six randomized controlled trials evaluated subcutaneous semaglutide 2.4 mg once weekly versus placebo in 3,962 overweight or obese adults without diabetes. Semaglutide led to significant reductions in body weight percentage (MD: -11.80% [95% CI -12.93, -10.68]; P < 0.00001), absolute body weight (MD: -12.2 kg [95% CI -13.3, -11.1]; P < 0.00001), BMI (MD: -4.5 kg/m2 [95% CI -4.9, -4.1]; P < 0.00001), and waist circumference (MD: -9.4 cm [95% CI -10.1, -8.8]; P < 0.00001). It also significantly improved blood pressure, blood glucose, C-reactive protein, and lipid profiles. Gastrointestinal adverse reactions were the most common adverse effect (RR: 1.49 [95% CI 1.38, 1.60]; P < 0.00001) and were generally mild to moderate and temporary.

Study type
Systematic review and meta-analysis of RCTs
Who was studied
3,962 overweight or obese adults without diabetes
What was measured
Body weight, BMI, waist circumference, cardiometabolic markers, and adverse effects

THE PAPER

Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial.

Qin W, Yang J, Deng C, Ruan Q, Duan K. Diabetes Obes Metab, 2024.

PubMed 38016699 ↗DOI 10.1111/dom.15386 ↗

Diabetes & blood sugarBlood pressureWeight & appetite

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.